REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $387.44 million. The enterprise value is $238.34 million.
Important Dates
The next estimated earnings date is Tuesday, February 25, 2025, after market close.
| Earnings Date | Feb 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 49.55 million shares outstanding. The number of shares has increased by 9.71% in one year.
| Current Share Class | 49.55M |
| Shares Outstanding | 49.55M |
| Shares Change (YoY) | +9.71% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 7.74% |
| Owned by Institutions (%) | 74.32% |
| Float | 40.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.45 |
| Forward PS | 1.56 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.48.
| Current Ratio | 3.05 |
| Quick Ratio | 2.93 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -52.13 |
Financial Efficiency
Return on equity (ROE) is -71.87% and return on invested capital (ROIC) is -29.81%.
| Return on Equity (ROE) | -71.87% |
| Return on Assets (ROA) | -26.03% |
| Return on Capital (ROIC) | -29.81% |
| Revenue Per Employee | $245,137 |
| Profits Per Employee | -$694,201 |
| Employee Count | 344 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -152,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.25% in the last 52 weeks. The beta is 1.28, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -47.25% |
| 50-Day Moving Average | 8.73 |
| 200-Day Moving Average | 11.84 |
| Relative Strength Index (RSI) | 45.02 |
| Average Volume (20 Days) | 1,247,335 |
Short Selling Information
The latest short interest is 6.04 million, so 12.20% of the outstanding shares have been sold short.
| Short Interest | 6.04M |
| Short Previous Month | 6.23M |
| Short % of Shares Out | 12.20% |
| Short % of Float | 14.91% |
| Short Ratio (days to cover) | 3.28 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $84.33 million and -$238.81 million in losses. Loss per share was -$5.00.
| Revenue | 84.33M |
| Gross Profit | -164.98M |
| Operating Income | -240.08M |
| Pretax Income | -241.23M |
| Net Income | -238.81M |
| EBITDA | -223.55M |
| EBIT | -240.08M |
| Loss Per Share | -$5.00 |
Full Income StatementBalance Sheet
The company has $255.46 million in cash and $145.81 million in debt, giving a net cash position of $132.76 million or $2.68 per share.
| Cash & Cash Equivalents | 255.46M |
| Total Debt | 145.81M |
| Net Cash | 132.76M |
| Net Cash Per Share | $2.68 |
| Equity (Book Value) | 301.42M |
| Book Value Per Share | 6.09 |
| Working Capital | 210.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$182.26 million and capital expenditures -$2.48 million, giving a free cash flow of -$184.74 million.
| Operating Cash Flow | -182.26M |
| Capital Expenditures | -2.48M |
| Free Cash Flow | -184.74M |
| FCF Per Share | -$3.73 |
Full Cash Flow StatementMargins
Gross margin is -195.65%, with operating and profit margins of -284.70% and -283.19%.
| Gross Margin | -195.65% |
| Operating Margin | -284.70% |
| Pretax Margin | -283.37% |
| Profit Margin | -283.19% |
| EBITDA Margin | -265.10% |
| EBIT Margin | -284.70% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.71% |
| Shareholder Yield | -9.71% |
| Earnings Yield | -64.35% |
| FCF Yield | -49.78% |
Analyst Forecast
The average price target for REGENXBIO is $35.55, which is 354.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.55 |
| Price Target Difference | 354.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 48.73% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -1.22 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.22 |
| Piotroski F-Score | 4 |